How Much Does Wegovy Cost in the UK? NHS and Private Prices

How much does Wegovy cost in the UK? Whether you are considering NHS treatment or a private prescription, understanding the full cost of Wegovy (semaglutide 2.4 mg) is essential before starting this prescription-only weight management medicine. Costs vary considerably depending on your eligibility, chosen provider, and whether you access treatment through specialist NHS services or a private clinic. This article explains current pricing, NHS criteria, private prescription routes, and the factors that influence overall treatment expenses, helping you make an informed decision about your options.

How Much Does Wegovy Cost in the UK?

Wegovy costs approximately £150 to £300 per month on a private prescription in the UK; NHS patients eligible under NICE TA875 pay only the standard prescription charge in England, or nothing in Scotland, Wales, and Northern Ireland.

Wegovy (semaglutide 2.4 mg) is a prescription-only medicine licensed for weight management in adults with obesity or overweight with weight-related health conditions. The cost of Wegovy in the UK varies significantly depending on whether it is obtained through the NHS or via private prescription.

Private prescription costs are typically in the range of £150 to £300 per month, though prices vary between providers and change over time; patients should check current prices directly with their chosen pharmacy or clinic before starting treatment. The treatment involves a gradual dose escalation over approximately 16 weeks (as set out in the UK Wegovy SmPC), starting at 0.25 mg weekly and increasing to the maintenance dose of 2.4 mg weekly. In some cases a clinician may extend the titration period based on individual tolerability; patients should follow their prescriber's guidance. Lower-dose pens may be priced differently by some suppliers during the escalation phase.

For those eligible for NHS treatment, Wegovy is provided within specialist weight management services alongside multicomponent lifestyle support, as required by NICE guidance (TA875). In England, dispensing may be subject to the standard NHS prescription charge (£9.90 per item as of 2024, per NHS England), though supply is often via hospital or homecare pathways which may have different charging arrangements. In Scotland, Wales, and Northern Ireland, prescriptions are free of charge. NICE guidance (TA875) limits NHS-funded treatment to a maximum of 2 years.^[5][6]

Supply constraints have at times affected Wegovy availability in the UK, which can influence access through both NHS and private routes. The SmPC does not set a maximum treatment duration; NHS funding is limited to 2 years per NICE TA875. Patients are advised to discuss costs and supply with their prescriber and pharmacy before commencing treatment.

NHS Availability and Prescription Criteria for Wegovy

NHS-funded Wegovy is available through specialist weight management services in England from September 2023, requiring a BMI of 35 kg/m² or above, at least one weight-related comorbidity, and a maximum treatment duration of 2 years per NICE TA875.

Wegovy became available on the NHS in England from September 2023, following NICE guidance (TA875) recommending its use within specialist weight management services.^[3][4] Access is highly restricted due to limited NHS capacity and strict eligibility criteria.

To qualify for NHS-funded Wegovy, adults must meet the following conditions:

• Have a body mass index (BMI) of 35 kg/m² or above (or 32.5 kg/m² or above for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean family backgrounds, who are at equivalent risk at lower BMI thresholds, per NICE TA875)

• Have at least one weight-related comorbidity, such as hypertension, type 2 diabetes, obstructive sleep apnoea, or cardiovascular disease

• Be treated within a specialist weight management service that provides multicomponent lifestyle support (dietary, physical activity and behavioural interventions), as required by NICE TA875

NICE guidance (TA875) specifies that NHS-funded treatment is limited to a maximum of 2 years.^[5][6] The typical pathway involves GP referral to a specialist weight management service, where treatment is initiated and monitored according to local protocols.

Due to high demand and limited specialist service capacity, many eligible patients face long waiting times or are unable to access NHS-funded treatment promptly. In Scotland, Wales, and Northern Ireland, local health boards and national agencies determine availability, and access may differ from England; patients in those nations should seek guidance from their GP or local health board. Patients who do not meet these criteria, or who cannot access specialist services, may consider private prescription routes if clinically appropriate.

Private Prescription Costs and Where to Buy Wegovy

Private Wegovy costs approximately £150 to £300 per month depending on dose and supplier; it can be obtained from GPhC-registered online pharmacies, private GP clinics, or high street pharmacies with a valid UK prescription.

For patients who do not meet NHS criteria or prefer faster access, Wegovy is available through private prescription from registered UK healthcare providers. Private costs are significantly higher than NHS prescription charges, and patients should budget for ongoing monthly expenses.

Typical private costs include:

• Medication cost: approximately £150 to £300 per month, depending on dose and supplier (prices vary and should be confirmed directly with the provider)

• Follow-up appointments: fees vary widely between providers; patients should ask for a full breakdown of consultation costs before committing to a service

Wegovy can be obtained privately through several routes:

Registered online pharmacies and telehealth services offer remote consultations and home delivery. These services typically require completion of a medical questionnaire and may include video consultations with prescribers.

Private GP clinics and weight management specialists can prescribe Wegovy following face-to-face assessment. This route may be preferable for patients with complex medical histories or those requiring more personalised monitoring.

High street pharmacies with private prescription services may dispense Wegovy if you have a valid private prescription from a UK-registered prescriber.

Important safety considerations: Only obtain Wegovy from legitimate, UK-regulated sources. The MHRA has issued warnings about counterfeit semaglutide products sold online.^[9] Verify that any online pharmacy displays the General Pharmaceutical Council (GPhC) registration and the UK distance-selling logo (as described in MHRA guidance on buying medicines online).^[12] Check that the prescribing service is regulated by the Care Quality Commission (CQC) in England, Healthcare Improvement Scotland (HIS) in Scotland, Healthcare Inspectorate Wales (HIW) in Wales, or the Regulation and Quality Improvement Authority (RQIA) in Northern Ireland. Never purchase prescription medicines from unregulated websites or social media sellers, as these may contain harmful substances or incorrect doses.

Factors That Affect the Price of Wegovy

Wegovy pricing varies based on dosage phase, supplier model, supply availability, and whether consultations are bundled; private medical insurance rarely covers weight management medicines in the UK.

Several factors influence the cost of Wegovy for individual patients, creating variation in overall treatment expenses.

Dosage and treatment phase: Wegovy requires dose escalation over approximately 16 weeks per the UK SmPC. Some suppliers price lower-dose pens differently from the maintenance-dose pen, though pricing structures vary between providers. Patients should confirm the cost at each dose level with their chosen provider before starting.

Supplier and service model: Prices vary between providers. Online telehealth platforms may offer different pricing from private clinics with face-to-face consultations. Some services offer subscription models with bundled consultations and medication; others charge separately for each element. Patients should ask for a clear breakdown of all costs, including consultations, before committing to any service, and compare total monthly costs across providers.

Supply and demand: Wegovy has experienced supply constraints since its launch, affecting UK availability. When supply is limited, access may be delayed and some pharmacies implement waiting lists. Patients should check current availability with their pharmacy.

Prescription-only status: Wegovy remains prescription-only in the UK, meaning all legitimate purchases require prescriber involvement. This adds consultation costs to the medication price. There is no over-the-counter version available.

Insurance coverage: Weight management medicines, including Wegovy, are not routinely covered by private medical insurance in the UK, as many policies classify them as lifestyle treatments. However, coverage terms differ between insurers and policies. Patients should check their own policy documents or contact their insurer directly to confirm what is and is not covered.

Bulk purchasing and payment plans: Some private providers offer discounts for purchasing multiple months upfront or provide payment plans to spread costs. Patients should ensure they can tolerate the medication before committing to large advance payments.

Is Wegovy Worth the Cost? Effectiveness and Alternatives

Wegovy produced average body weight reductions of approximately 12 to 15% in clinical trials when combined with lifestyle interventions; alternatives include orlistat, Saxenda, structured lifestyle programmes, and bariatric surgery for eligible patients.

Determining whether Wegovy represents good value requires weighing its clinical effectiveness against cost and considering alternative approaches to weight management.

Clinical effectiveness: Wegovy has demonstrated significant weight loss in clinical trials. The STEP trial programme (including STEP 1, Wilding et al., NEJM 2021, and related publications) showed that patients lost an average of approximately 12 to 15% of their body weight over 68 weeks when combined with lifestyle interventions, compared with approximately 2 to 3% with placebo. Improvements in cardiovascular risk factors, including blood pressure and cholesterol, were also observed. The SELECT trial (NEJM) demonstrated a reduction in major adverse cardiovascular events in people with established cardiovascular disease and overweight or obesity; patients should note that the current UK-licensed indications should be checked against the up-to-date UK Wegovy SmPC, as the licensed indication may differ from trial populations.^[15][16]

Mechanism of action: Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that works by increasing satiety, reducing appetite, and slowing gastric emptying.^[1][2] This makes it easier for patients to adhere to reduced-calorie diets. Weight regain commonly occurs if treatment is discontinued without maintained lifestyle changes.

Common adverse effects include nausea, vomiting, diarrhoea, constipation, and abdominal pain, particularly during dose escalation. Most gastrointestinal symptoms improve over time. Rare but serious risks include pancreatitis and gallbladder disease, as described in the UK Wegovy SmPC.^[1] If you develop severe or persistent abdominal pain, seek immediate medical attention, as this may be a sign of pancreatitis. The SmPC contains a precaution about thyroid C-cell tumours observed in animal studies, though there is no confirmed link in humans.^[1][11] Wegovy is contraindicated in pregnancy and should be discontinued at least 2 months before a planned pregnancy. People with type 2 diabetes, particularly those on insulin or insulin secretagogues, should be monitored for hypoglycaemia and for diabetic retinopathy. Wegovy should not be used concurrently with other GLP-1 receptor agonists.

Alternatives to consider:

• Lifestyle interventions: Evidence-based weight management programmes combining dietary modification, physical activity, and behavioural support remain the foundation of treatment and cost significantly less

• Other medications: Orlistat (available over-the-counter or on prescription) has more modest efficacy; current prices should be checked with a pharmacist or pharmacy, as they vary. Saxenda (liraglutide 3 mg), another GLP-1 receptor agonist, requires daily injections; current pricing should be confirmed with providers

• Bariatric surgery: For patients with a BMI of 40 kg/m² or above (or 35 kg/m² or above with significant comorbidities), surgery may be considered via NHS referral through specialist assessment and commissioning pathways; eligibility and access are determined by current NICE obesity guidance and local commissioning arrangements

If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk or by searching for MHRA Yellow Card in the Google Play or Apple App Store.

Frequently Asked Questions